ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.

Br J Cancer · 2013 · PMC3798971 · PMID 24064970

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

For both antibodies, there was a significant trend for ERCC1 expression to be higher in p16-negative than in p16-positive tumours, although all categorical expression levels were observed in both.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.